MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$45.28 USD
+2.22 (5.16%)
Updated Aug 8, 2024 03:44 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
MoonLake Immunotherapeutics [MLTX]
Reports for Purchase
Showing records 21 - 40 ( 95 total )
Company: MoonLake Immunotherapeutics
Industry: Unclassified
MoonLake Immunotherapeutics Management Call Invite - Dec. 7, 2023 at 10AM ET
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Poised to Enter Pivotal Development; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Optimized Entry and Exit Levels for MLTX 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Q3: SLK''s Profile a Strategic Fit for Big Pharma Focused on II; PT to $92
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Interim Psoriatic Arthritis Data Look Favorable; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Diving Deep into The Ph2 PsA Data; Baseless Selloff Creates Buying Opportunity
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Positive 12wk Ph2 SLK/PsA Results; More Color on Investor Call @ 8AM ET
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Biotechnology-The Wedbush Monthly Check-Up: November 2023
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Highlights from KOL Call: Hitting the High Bar in HS
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Roche Telavant Acquisition Underscores Value Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
SLK Longer-Term HS Data Continue to Impress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R